Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company developing allogeneic gamma delta CAR T cell therapies for autoimmune diseases and cancer. The ACET news feed on Stock Titan aggregates company-issued updates, SEC-linked announcements, and other coverage related to Adicet’s clinical programs, capital markets activity, and regulatory interactions.
Investors and followers of Adicet Bio can use this page to review news on its lead program, prulacabtagene leucel (prula-cel, formerly ADI-001), an investigational allogeneic gamma delta CAR T therapy targeting B cells via an anti-CD20 CAR. Company releases have highlighted Phase 1 data in lupus nephritis and systemic lupus erythematosus, enrollment across additional autoimmune indications such as systemic sclerosis, idiopathic inflammatory myopathy, stiff person syndrome, ANCA associated vasculitis and treatment-refractory rheumatoid arthritis, and regulatory designations including Fast Track status for several of these conditions.
The ACET news stream also reflects Adicet’s oncology work, including updates on ADI-212, a next-generation, gene-edited and armored gamma delta CAR T candidate targeting prostate-specific membrane antigen in metastatic castration-resistant prostate cancer. Preclinical data presentations, plans for regulatory filings, and development timelines are typically communicated through press releases and associated 8-K filings.
Beyond clinical and scientific developments, Adicet Bio’s news includes information on registered direct offerings of common stock and pre-funded warrants, reverse stock split decisions, Nasdaq listing status notices, workforce and pipeline prioritization actions, and participation in healthcare conferences. By reviewing this curated ACET news page, readers can follow how Adicet reports progress in its autoimmune and oncology pipelines, how it manages its capital structure, and how key milestones are communicated through official channels.
Adicet Bio, Inc. (Nasdaq: ACET) has announced a public offering of 6,250,000 shares of common stock priced at $14.00 per share, aiming for gross proceeds of approximately $87.5 million. The company has granted underwriters a 30-day option to purchase an additional 937,500 shares. The offering is set to close around December 10, 2021, pending customary closing conditions. This offering is conducted under a previously effective shelf registration statement with the SEC.
Adicet Bio, Inc. (Nasdaq: ACET) has announced an underwritten public offering of its common stock, granting underwriters a 30-day option for an additional 15% of shares sold at the public offering price. The offering is contingent on market conditions. Shares will be sold under a shelf registration statement effective since March 30, 2021. Jefferies LLC and Guggenheim Securities, LLC are acting as joint book-running managers. This press release does not constitute an offer to sell or a solicitation for the purchase of securities.
Adicet Bio announced promising interim results from its Phase 1 study of ADI-001, a gamma delta CAR T cell therapy targeting B-cell Non-Hodgkin's Lymphoma. As of November 22, 2021, six patients received ADI-001, with an overall response rate (ORR) of 75% and a complete response (CR) rate of 50%. Notably, no serious adverse events were reported. The findings support the therapy's safety and potential effectiveness, highlighting its ability to offer an off-the-shelf treatment option. Further data is anticipated in the first half of 2022, showcasing the ongoing progress of Adicet's innovative platform.
Adicet Bio (Nasdaq: ACET) has announced a webcast on December 6, 2021, at 8:30 AM EST to present interim data from the Phase 1 study of ADI-001, an allogeneic gamma delta CAR T cell therapy targeting CD20 for B Cell Non-Hodgkin’s Lymphoma. This presentation will feature expert insights from Dr. Sattva Neelapu and Adicet's management team. The study aims to evaluate the safety and tolerability of ADI-001, marking a significant milestone in cancer treatment approaches.
Adicet Bio, Inc. (Nasdaq: ACET) announced the appointment of Michael G. Kauffman, M.D., Ph.D., to its Board of Directors. With over 20 years of experience in oncology drug development, Kauffman is expected to enhance the company’s gamma-delta CAR-T therapy initiatives. His track record includes leadership roles in various biopharmaceutical firms and significant contributions to drug approvals. Adicet focuses on developing off-the-shelf gamma delta T cell therapies aimed at improving cancer treatment outcomes, which can potentially offer benefits over existing therapies.
Adicet Bio, a biotechnology company focused on allogeneic gamma delta T cell therapies, presented promising preclinical data for its candidate ADI-002 at the 36th SITC Annual Meeting. The GPC3-targeted CAR-T therapy showed significant antitumor activity in mice without off-target effects. Findings reveal ADI-002's potential for targeting solid tumors, particularly in liver and lung cancers, demonstrating potent cytotoxicity and enhanced proliferation. Notably, ADI-002 maintained a naïve-like phenotype and exhibited reduced alloreactive potential, positioning it as a strong candidate for further clinical evaluation.
Adicet Bio (ACET) reported a net loss of $14 million for Q3 2021, an improvement from $14.8 million in Q3 2020. The company's cash position increased to $192.2 million, sufficient to fund operations through mid-2023. Key developments include ongoing Phase 1 trials of ADI-001 for Non-Hodgkin's Lymphoma, with interim results expected by year-end, and a collaboration with Twist Bioscience to enhance CAR-T therapy development. G&A expenses decreased significantly to $5.2 million, while R&D expenses rose to $11.9 million as clinical activities ramped up.
Adicet Bio, Inc. (Nasdaq: ACET) announced that CEO Chen Schor will present at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 4:00 pm ET. The event details, including access to a live audio webcast, are available on Adicet's investor website. The company is focused on developing innovative allogeneic gamma delta T cell therapies for cancer and other diseases, enhancing tumor targeting and immune response.
Adicet Bio, Inc. (Nasdaq: ACET) announced that its lead candidate, ADI-001, will be presented at the 63rd American Society of Hematology Annual Meeting on December 12, 2021. The presentation will detail the Phase 1 study aimed at evaluating the safety and tolerability of ADI-001, targeted at treating B Cell Malignancies. Interim clinical data is expected by the end of 2021. The abstract will also be published in Blood's November supplemental issue. Adicet is focused on developing allogeneic gamma delta T cell therapies for cancer.
Adicet Bio, Inc. (Nasdaq: ACET) has announced the promotion of Blake Aftab, Ph.D., to Senior Vice President and Chief Scientific Officer. Dr. Aftab's new role focuses on expanding Adicet’s pipeline for cancer therapies, particularly in solid and hematologic tumors. His leadership is expected to enhance ongoing research, including the Phase 1 trial of ADI-001 for non-Hodgkin’s lymphoma. The company anticipates revealing interim data for ADI-001 later this year, marking a significant development in gamma delta CAR-T cell therapy.